Loading...
•
Sep 30, 2022
Omeros Q3 2022 Earnings Report
Omeros reported a net loss for Q3 2022 and provided updates on its clinical development programs and regulatory activities.
Key Takeaways
Omeros Corporation reported a net loss of $17.5 million for the third quarter of 2022. The company earned royalties of $16.5 million on net sales of OMIDRIA and sold an interest in a portion of future OMIDRIA royalty receivables for $125.0 million. The FDA denied the company's appeal regarding the biologics license application for narsoplimab in TA-TMA.
Omeros earned $16.5 million in royalties from OMIDRIA sales in Q3 2022.
Net loss for Q3 2022 was $17.5 million, or $0.28 per share.
Omeros sold an interest in future OMIDRIA royalty receivables for $125.0 million.
FDA denied the appeal of the complete response letter for narsoplimab in TA-TMA but proposed a path forward for resubmission.
Forward Guidance
Omeros anticipates data from clinical trials and is assessing potential next steps for narsoplimab approval, while also expecting news from other programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...